Capabilities

  • Cristalography.jpg
  • Histology.jpg
  • Medium throuput pipeting.jpg
  • Microscopy.jpg
  • NMR.jpg
  • NMR2.jpg
  • Plate Reader.jpg

 

Our expanding drug discovery infrastructure includes access to extensive facilities such as:

 

• High resolution NMR and X-ray crystallography

 

• Multimode plate readers

 

• Sterile assisted pipetting systems for medium throughput screening applications

 

• Microfluidics systems for enzyme kinetic assays

 

• Leicester Imaging Technologies (light and electron microscopy)

 

• Histology Facility (sample preparation, IHC and IF)

 

• Containment Level 3 facilities (ACDP Category 3 organisms)

 

• World class animal facilities, including pre-clinical imaging (MRI, micro-CT, IVIS and ultrasound)

 

Our dedicated team of laboratory research support can provide assistance with:

• Assay design and development

• Early hit-to-lead to proof of concept work

• In vitro activity screens, in silico screening and assessment of candidate molecules in animal aswell as in vivo and ex vivo models of disease

• Access to internal core facilities at Leicester such as genomic services, proteomics, imaging,

bioinformatics and histology

Our expertise is focused on:

in vitro cell culture – mammalian cells (primary and established) with both adherent and suspension lines

• Cell-based compound screening assays including in vitro cytotoxicity, viability and cell proliferation assays, cell migration and senescence

in vivo models – developing and working with established murine models of human disease, explant models, xenograft cancer models (including the assessment of novel chemotherapy compounds)

• Patient samples – good clinical practice (GCP) trained and HTA certified, experienced in processing patient blood and tissue samples

• Enzyme isolation and kinetics, membrane transport kinetics

• Protein crystallography and protein structure determination

• Monoclonal antibodies – antibody purification, antibody binding and toxicity assays, collaborating with commercial partners in the development of antibody drug conjugates (ADCs)

• Molecular biology – including DNA, RNA and protein extraction (from tissues and cultured cells), Southern, and western blotting, PCR (including ligation-mediated), expression studies (qPCR, DNA and RNA, micro RNAs, microarrays), FACS and ELISAs, cloning, transfection, tNGS.

• Microbiology – handling of category 2 and 3 microorganisms and optimisation of minimal mediums for use in bio-reactors, compound screening through Minimum Inhibitory Concentration (MIC) and Minimum Bactericidal Concentration (MBC) assays, according to EUCAST standards.

 

Discover:

Share this page:

Contact us

LD3 Research Manager, 

Dr. Christine Alberti-Segui:

+44 (0) 116 252 5174

LD3 Office:

+44 (0) 116 252 3342              

drugdiscovery@le.ac.uk 

Contact Details

College of Life Sciences
University of Leicester
Maurice Shock Building
University Road
Leicester
LE1 7RH